FindTrial
Sign In

Placebo + ADT

DRUG3 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

DepressionDepressive DisorderDepressive Disorder, MajorMental DisordersMood Disorders

Phase 3

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
CompletedNCT01360632
Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2
Start: 2011-06-30End: 2013-09-30Updated: 2016-01-01
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
CompletedNCT01360645
Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2
Start: 2011-07-31End: 2013-06-30Updated: 2015-11-26
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
CompletedNCT02196506
Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2
Start: 2014-07-31End: 2016-05-31Updated: 2018-08-21

Related Papers

Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials.
2025-10-01
Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials
Frontiers in Psychiatry2025-08-072 citations
Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: <i>Post Hoc</i> Analysis of Randomized Controlled Trials
The International Journal of Neuropsychopharmacology2025-07-03
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
CNS Drugs2024-10-182 citations
Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress
Journal of Clinical Psychopharmacology2024-02-294 citations
Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder
The Journal of Clinical Psychiatry2023-08-244 citations
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole
The Journal of Clinical Psychiatry2019-10-0112 citations
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Journal of Clinical Psychopharmacology2019-04-0224 citations
Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
2019-03-0116 citations
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies.
2018-12-2019 citations
Brexpiprazole: a step forward for precision medicine in resistant depression
Expert Opinion on Pharmacotherapy2018-09-243 citations
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder
The Journal of Clinical Psychiatry2018-05-2165 citations
123 Adjunctive Brexpiprazole in Patients With MDD and Symptoms of Anxiety: Results From Post-Hoc Analyses of Three Placebo-Controlled Studies
CNS Spectrums2018-02-01
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
2016-05-1225 citations
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder
The Journal of Clinical Psychiatry2015-08-03171 citations
Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants
The Journal of Clinical Psychiatry2015-08-03160 citations